TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16990498

Group type: EXPERIMENTAL
Intervention: Hypoxic training (H group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normoxic training (Nor group)
Number of subjects: 18
Study: 15677779

Group type: EXPERIMENTAL
Intervention: PACCTS (Pro‐Active Call Center Treatment Support)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 591
Study: 11865416

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (400/100 mg or 400/200 mg twice daily)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir plus Nevirapine (200 mg 2x/day) and nucleoside reverse-transcriptase inhibitors
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir treatment
Number of subjects: 70
Study: 10541953

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 9
Study: 7874950

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus NIPSV (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional therapy (n = 20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus NIPSV (n = 17, subgroup with PaCO2 > 45 mm Hg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional therapy (n = 17, subgroup with PaCO2 > 45 mm Hg)
Number of subjects: 41
Study: 2211567

Group type: EXPERIMENTAL
Intervention: Buspirone 5-10 mg t.i.d. for 6 weeks
Number of subjects: 230

Group type: COMPARATOR
Intervention: Oxazepam 10-20 mg t.i.d. for 6 weeks
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 230
Study: 322325

Group type: EXPERIMENTAL
Intervention: gliclazide (S 852)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: glibenese
Number of subjects: 12
Study: 30011020

Group type: EXPERIMENTAL
Intervention: SmokeFree Baby app (v1)
Number of subjects: 565
Study: 28431870

Group type: EXPERIMENTAL
Intervention: 20% Mannitol (MT)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 3% Hypertonic Saline (HTS)
Number of subjects: 2
Study: 26592226

Group type: EXPERIMENTAL
Intervention: Fascial Abrasion Technique (FAT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Foam Rolling (FR)
Number of subjects: 20
Study: 23905374

Group type: EXPERIMENTAL
Intervention: Salvianolate (200 mg/day) with routine Western medical treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: Routine Western medical treatment (Control)
Number of subjects: 83
Study: 20659908

Group type: EXPERIMENTAL
Intervention: Unfractioned heparin (UFH)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 40
Study: 19156019

Group type: EXPERIMENTAL
Intervention: Intervention delivered by Speech and Language Pathologists/Therapists targeting CAS
Number of subjects: 31

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 31
Study: 16542205

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Talinolol (100 mg daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SLCO1B1*1b allele carriers
Number of subjects: 18
Study: 15264506

Group type: EXPERIMENTAL
Intervention: Cisatracurium (GC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rocuronium (GR)
Number of subjects: 32
Study: 11522675

Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamp (blood glucose reduced to 54 mg/dl)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hyperinsulinemic-euglycemic clamp (blood glucose maintained near 100 mg/dl)
Number of subjects: 26
Study: 9233903

Group type: EXPERIMENTAL
Intervention: Mesterolone (MES) 100 mg/d
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 160 mg/d
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 250 mg i.m./21 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 1200 mg crystalline testosterone (TPEL) subcutaneously implanted
Number of subjects: 55
Study: 8502509

Group type: EXPERIMENTAL
Intervention: Ritalin (0.3 mg/kg per dose)
Number of subjects: 206
Study: 3102211

Group type: EXPERIMENTAL
Intervention: Early treatment group (TG) with CDP of 6 cm water pressure applied at birth by the nasopharyngeal route.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (CG) with CDP applied when indicated for established criteria (pO2 less than 50 mmHg in FiO2 greater than 0.5).
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (CG) with CDP applied when indicated for established criteria.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (TG and CG).
Number of subjects: 82
Study: 29938412

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 2% (Group A)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Sevoflurane (Group B)
Number of subjects: 710
Study: 27619831

Group type: EXPERIMENTAL
Intervention: Rockwood Instability programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watson MDI programme
Number of subjects: 0
Study: 26238225

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23619815

Group type: EXPERIMENTAL
Intervention: Tympanoplasty type I using pure perichondrium
Number of subjects: 80
Study: 20565229

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide (Spiriva)
Number of subjects: 19000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19000
Study: 18700624

Group type: EXPERIMENTAL
Intervention: Haemaccel (10 ml/kg intravenously over 10‐15 minutes)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Injection ephedrine (0.2 mg/kg iv)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no study medication)
Number of subjects: 120
Study: 15696985

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate foam 1% (CF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clindamycin phosphate topical gel 1% (CG)
Number of subjects: 0
Study: 12601094

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study: 10548211

Group type: EXPERIMENTAL
Intervention: Dalteparin (20 units/kg bolus, 10 units/kg/hr infusion)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Heparin (2000-5000 units bolus, 10 units/kg/hr infusion, titrated to 70-80 secs aPTT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 57
Study: 8522709

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 36
Study: 1841043

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Number of subjects: 78
Study: 6301320

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus immune globulin administered before and for 11 weeks after transplantation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Granulocyte transfusions from seropositive donors
Number of subjects: 36
Study: 31934788

Group type: EXPERIMENTAL
Intervention: Starting Early Program (StEP) intervention with prenatal/postpartum individual nutrition counseling and nutrition and parenting support groups
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Starting Early Program (StEP) intervention
Number of subjects: 533
Study: 31664156

Group type: EXPERIMENTAL
Intervention: Buffered acidic saline solution (pH 5.2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isotonic saline solution (pH 6)
Number of subjects: 14
Study: 29063837

Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 134
Study: 27095804

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab
Number of subjects: 0
Study: 24560062

Group type: EXPERIMENTAL
Intervention: Ranolazine added to standard-of-care (SoC) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SoC) treatment alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranolazine added to SoC
Number of subjects: 0
Study: 22834720

Group type: EXPERIMENTAL
Intervention: Conservative care (IV epidural preload volume of <500 mLs continuing at an hourly rate of 75-100 mL/h)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (epidural preload volume of ≥500 mLs and an hourly rate >125 mL/h)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Conservative care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 19273551

Group type: EXPERIMENTAL
Intervention: Antioxidant group (1 g l-ascorbic acid, 400 IU alpha-tocopherol acetate, 600 mg alpha-lipoic acid in four divided doses)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Antioxidant group
Number of subjects: 83
Study: 18558509

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16238973

Group type: EXPERIMENTAL
Intervention: External radiotherapy combined with HDR brachytherapy (46 Gy external irradiation and 2 HDR fractions of 1150 cGy each)
Number of subjects: 100
Study: 12383043

Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium 10mg + aspirin 975mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium 10mg + piroxicam 20mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fondaparinux sodium 10mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piroxicam 20mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piroxicam 20mg + fondaparinux sodium 10mg
Number of subjects: 0
Study: 10369196

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide, dipyridamole, warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 0
Study: 8537694

Group type: EXPERIMENTAL
Intervention: Levosulpiride (L) 75 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metoclopramide (M) 30 mg/day
Number of subjects: 30
Study: 2406218

Group type: EXPERIMENTAL
Intervention: Dipivefrin 0.1% twice daily during the holiday
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Timolol therapy restored after holiday
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dipivefrin-treated group (60 days treatment)
Number of subjects: 39
Study: 6996779

Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 307

Group type: COMPARATOR
Intervention: Medical units
Number of subjects: 307
Study: 30651117

Group type: EXPERIMENTAL
Intervention: 100 Mile Club walking/running program
Number of subjects: 13

Group type: COMPARATOR
Intervention: CHALK/Just Move classroom activity break PA program
Number of subjects: 13
Study: 28241070

Group type: EXPERIMENTAL
Intervention: Bisensory‐DBM with scented cream
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Multisensory‐DBM with scented cream associated with audiovisual material
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 93
Study: 24604029

Group type: EXPERIMENTAL
Intervention: 2% taurolidine lock (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.35% taurolidine + citrate lock (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control - saline flush (group C)
Number of subjects: 30
Study: 23485514

Group type: EXPERIMENTAL
Intervention: Lipoic acid (1200 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22432727

Group type: EXPERIMENTAL
Intervention: insuVida™ (hydrolyzed casein)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: insuVida™ plus added leucine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: unhydrolyzed casein
Number of subjects: 36

Group type: COMPARATOR
Intervention: insuVida™, unhydrolyzed casein, and placebo
Number of subjects: 36
Study: 18163196

Group type: EXPERIMENTAL
Intervention: Eptifibatide (two 180 microg/kg boluses followed by infusion at 2.0 and 1.3 microg/kg/min for 24 and 48 h, respectively)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (treated without GP IIb‐IIIa antagonists)
Number of subjects: 25
Study: 17588545

Group type: EXPERIMENTAL
Intervention: D-cycloserine (125 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15765857

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mental stress (MS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Baseline (PRE)
Number of subjects: 10
Study: 11159249

Group type: EXPERIMENTAL
Intervention: 200 mg of dextromethorphan given eight hourly
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 9773893

Group type: EXPERIMENTAL
Intervention: NaCl-NaCitrate beverage (185 mEq x L(‐1) Na+, 283 mOsm x kg(‐1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NaCl-NaCitrate beverage (21.6 mEq x L(‐1) Na+, 365 mOsm x kg(‐1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Water at ALT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Water on the ground
Number of subjects: 10
Study: 8144825

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2843314

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg intravenously, followed by a continuous infusion of 10 mg/h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone and Saline
Number of subjects: 10
Study: 31629030

Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse with 0.1% CuNp (ERcu)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: self‐etch with 0.1% CuNp (SEcu)
Number of subjects: 36

Group type: COMPARATOR
Intervention: etch‐and‐rinse without CuNp (ERct)
Number of subjects: 36

Group type: COMPARATOR
Intervention: self‐etch without CuNp (SEct)
Number of subjects: 36
Study: 28522759

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IB; 10 mg/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study: 26226987

Group type: EXPERIMENTAL
Intervention: High-dose impact-loading (80 jumps per session)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Moderate-dose impact-loading (40 jumps per session)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 42
Study: 23260857

Group type: EXPERIMENTAL
Intervention: PGS with transfer on day 5 (AMA study)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Blastocyst transfer on day 5 (AMA study)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: PGS with transfer on day 5 (RIF study)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Blastocyst transfer on day 5 (RIF study)
Number of subjects: 274
Study: 21216518

Group type: EXPERIMENTAL
Intervention: LUAO+M
Number of subjects: 332

Group type: COMPARATOR
Intervention: CISH
Number of subjects: 332
Study: 18416075

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion and Chinese Tuina
Number of subjects: 92

Group type: COMPARATOR
Intervention: Acupuncture-moxibustion
Number of subjects: 92
Study: 17172188

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 60
Study: 14529447

Group type: EXPERIMENTAL
Intervention: Dartmouth-regimen combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single agent chemotherapy
Number of subjects: 0
Study: 11120515

Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise 3 to 5 times a week for the remainder of pregnancy
Number of subjects: 46

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise
Number of subjects: 46
Study: 11248877

Group type: EXPERIMENTAL
Intervention: High alpha-linolenic formula (HLF)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low alpha-linolenic formula (LLF)
Number of subjects: 63
Study: 8325826

Group type: EXPERIMENTAL
Intervention: Asthma self-management program
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Asthma self-management program with progressive relaxation training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Asthma self-management program (for children with low self-care practices)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (initially maintained)
Number of subjects: 27
Study: 3937367

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylactic antibiotics
Number of subjects: 0
Study: 29055814

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention (diet, exercise, cognition, and vascular risk management)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Regular health advice (Control)
Number of subjects: 1260
Study: 27207435

Group type: EXPERIMENTAL
Intervention: Pain-related activity interference
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Fatigue-related activity interference
Number of subjects: 154
Study: 24723282

Group type: EXPERIMENTAL
Intervention: Ceftobiprole 500 mg every 8 hours
Number of subjects: 781

Group type: COMPARATOR
Intervention: Ceftazidime 2 g every 8 hours plus linezolid 600 mg every 12 hours
Number of subjects: 781
Study: 22240497

Group type: EXPERIMENTAL
Intervention: Pycnogenol (200 mg/day) for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pycnogenol (200 mg/day)
Number of subjects: 23
Study: 19855311

Group type: EXPERIMENTAL
Intervention: Maximal strength training (half-squats, 4 sets of 4 repetitions maximum, 3 times per week for 8 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (normal endurance training)
Number of subjects: 16
Study: 18241647

Group type: EXPERIMENTAL
Intervention: Yiqing Shuangjie Capsule (treatment group A)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Yiqing Shuangjie Tablet (treatment group B)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Chaihuang Tablet and Yiqing Shuangjie Capsule analogues (control group)
Number of subjects: 360
Study: 15763605

Group type: EXPERIMENTAL
Intervention: Combination oxycodone 5 mg/ibuprofen 400 mg
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456

Group type: COMPARATOR
Intervention: Oxycodone alone
Number of subjects: 456

Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 456
Study: 12937311

Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2.27% glucose
Number of subjects: 50
Study: 11200017

Group type: EXPERIMENTAL
Intervention: gated 99Tc(m)-sestamibi (MIBI) SPECT
Number of subjects: 33
Study: 9181183

Group type: EXPERIMENTAL
Intervention: Low doses of synthetic steroids administered orally starting on day 8 of the menstrual cycle (group I)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low doses of synthetic steroids administered orally starting on day 10 of the menstrual cycle (group II)
Number of subjects: 10
Study: 1543034

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 31
Study: 3935376

Group type: EXPERIMENTAL
Intervention: gliclazide
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: glibenclamide
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: gliquidone
Number of subjects: 96
Study: 28924729

Group type: EXPERIMENTAL
Intervention: Dor fundoplication
Number of subjects: 73

Group type: COMPARATOR
Intervention: Toupet fundoplication
Number of subjects: 73
Study: 27015382

Group type: EXPERIMENTAL
Intervention: Extended sleep (EXT, 9.8 ± 0.1 h time in bed)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Habitual sleep (HAB, 8.2 ± 0.1 h time in bed)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Extended sleep (EXT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Habitual sleep (HAB)
Number of subjects: 12
Study: 25247033

Group type: EXPERIMENTAL
Intervention: Hand-on-needle (HN) technique
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hand-on-syringe (HS) technique
Number of subjects: 10
Study: 22194379

Group type: EXPERIMENTAL
Intervention: Vertebral perforation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Vertebroplasty (PVP)
Number of subjects: 108
Study: 20482511

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study: 18666717

Group type: EXPERIMENTAL
Intervention: Manuka honey
Number of subjects: 108

Group type: COMPARATOR
Intervention: Hydrogel
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 11704703

Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (dihydropyridine calcium channel blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrendipine monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis based on Syst-Eur data
Number of subjects: 0
Study: 9414371

Group type: EXPERIMENTAL
Intervention: Human factors design guidance
Number of subjects: 0
Study: 8500236

Group type: EXPERIMENTAL
Intervention: V‐HeFT I (prazosin, hydralazine plus isosorbide dinitrate, placebo)
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: V‐HeFT II (prazosin, hydralazine plus isosorbide dinitrate, placebo, enalapril)
Number of subjects: 1446

Group type: COMPARATOR
Intervention: Enalapril treatment group
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: V‐HeFT I
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: V‐HeFT II
Number of subjects: 1446
Study: 2830895

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29486039

Group type: EXPERIMENTAL
Intervention: Bag-Mask Ventilation (BMV)
Number of subjects: 2043

Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 2043